Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

serious AEs, compared with 7 percent and 5 percent of patients in the golimumab 50 mg and golimumab 100 mg groups, respectively. Serious infections were reported in 3 percent, 3 percent and 1 percent of patients, and injection site reactions (ISR) through week 16 occurred in 3 percent, 4 percent and 11 percent of patients in the placebo, golimumab 50 mg and golimumab 100 mg groups, respectively. The most commonly reported ISR was erythema, a redness of the skin due to inflammation. No serious or severe ISRs were reported, and none led to the discontinuation of patients in the study. Antibodies to golimumab were detected in 4 percent of golimumab-treated patients (50 mg and 100 mg).

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite methotrexate therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus methotrexate, golimumab 100 mg plus placebo or placebo plus methotrexate at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Through week 24, 68 percent of patients in both the combined golimumab plus methotrexate groups and the placebo plus methotrexate group experienced at least one AE. Nine percent of patients in the combined golimumab plus methotrexate groups experienced a serious AE compared with 4 percent of patients receiving placebo plus methotrexate. Three percent of patients in the combined golimumab plus methotrexate groups and 1 percent in the group receiving placebo plus methotrexate experienced serious infections. Rates of ISRs were 5 percent in the combined golimumab plus methotrexate groups and 3 percent in the group receiving placebo plus methotrexate. Two percent of golimumab-treated patients developed antibodies. Four patients
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 BioStructures, LLC, a privately ... a milestone of 4,000 implantations of Signafuse® Bioactive ... in early 2014 as a bone void filler ... procedures.  This is a distinguished status among recently ... of new synthetic products have received clearance with ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
(Date:7/27/2015)... , July 27, 2015 According ... by Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative ... , Europe , Asia-Pacific ... 2019", The global biopreservation media market was valued at $247.7 ... $571.5 million by 2019, at a CAGR of 18.2% between ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3
... to the anterior cruciate ligament (ACL) is fairly common, ... corrected through surgery, the injury can lead to increased ... The problem is that fluid in the knee joint, ... of the injury and begins to deteriorate. A new ...
... DENVER , Aug. 5 Forensic ... services for drug and alcohol abuse, has announced the ... is the first lab in the nation to develop ... in saliva, a chemical produced by the body after ...
... Oncimmune® (USA) LLC , provider of Early ... and the early detection of lung cancer , today announced ... the test. The study titled " Clinical Validation of an Autoantibody ... at Annals of Oncology , Oxford Journals, or at Oncimmune,s ...
Cached Biology Technology:Lubricating the knee cartilage after ACL injury may prevent osteoarthritis 2Lubricating the knee cartilage after ACL injury may prevent osteoarthritis 3Forensic Laboratories Develops First Oral Fluid Test for Ethyl Sulfate Detection 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 2New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 3New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 4New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 5New Study Demonstrates Clinical Validity of EarlyCDT-Lung™ 6
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... postmenopausal women and people of all ages, actually ... solution to help prevent fractures and osteoporosis: eating dried plums. ... figs, dates, strawberries and raisins, and none of them come ... dried plums, or prunes, have," said Bahram H. Arjmandi, Florida ...
... cloud computing becomes the next big consumer techo trend, ... physically store everything from playlists to photos, it,s ... is done. Using the cloud model as inspiration, biomedical ... the Translational Research Informatics and Data management grid (TRIAD), ...
... partnering organizations have discovered a remarkably primitive eel in a ... This fish exhibits many primitive anatomical features unknown in the ... eels, resulting in its classification as a new species belonging ... published online in the Proceedings of the Royal Society ...
Cached Biology News:No bones about it: Eating dried plums helps prevent fractures and osteoporosis 2Biomedical research gets its head into cloud computing 2Biomedical research gets its head into cloud computing 3Biomedical research gets its head into cloud computing 4Scientists discover the most primitive living eel 2
... system, 100-120 V, is used for biolistic ... handheld device employs an adjustable helium pulse ... gold microcarriers from the inner wall of ... cells. This system has a 2 square-centimeter ...
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: